NCT04183166View on ClinicalTrials.gov

A Clinical Trial Evaluating TG4050 in Head and Neck Cancer

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

December 12, 2019

Primary Completion Date

December 30, 2027

Study Completion Date

December 30, 2028

Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
DRUG

TG4050

Subcutaneous injections weekly for the first 6 weeks and then every 3 weeks

Trial Locations (14)

13000

Hôpital de la Timone, Marseille

15076

Complejo Hospitalario Universitario de Santiago, Santiago de Compostela

28040

Hospital Clínico San Carlos, Madrid

28046

Hospital Universitario La Paz, Madrid

29010

Hospital Regional Universitario de Málaga - Hospital Civil, Málaga

31100

IUCT Toulouse, Toulouse

32224

Mayo Clinic Jacksonville, Jacksonville

33000

Hôpital Saint André - CHU de Bordeaux, Bordeaux

75005

Institut Curie, Paris

94805

Institut Gustave Roussy, Villejuif

08035

Hospital Universitari Vall d Hebrón, Barcelona

08908

Institut Català d Oncologia - Hospital Duran i Reynals, Barcelona

L7 8YA

NHS Clatterbridge Cancer Center, Liverpool

L9 7AL

Aintree University Hospital NHS Fondation Trust, Liverpool

Sponsors

Lead Sponsor

Transgene
All Listed Sponsors
lead

Transgene

INDUSTRY

NCT04183166 - A Clinical Trial Evaluating TG4050 in Head and Neck Cancer | Biotech Hunter | Biotech Hunter